JP2003508527A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003508527A5 JP2003508527A5 JP2001522211A JP2001522211A JP2003508527A5 JP 2003508527 A5 JP2003508527 A5 JP 2003508527A5 JP 2001522211 A JP2001522211 A JP 2001522211A JP 2001522211 A JP2001522211 A JP 2001522211A JP 2003508527 A5 JP2003508527 A5 JP 2003508527A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- ring atoms
- ring
- unsubstituted
- nhcoch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000006413 ring segment Chemical group 0.000 description 32
- 150000001875 compounds Chemical class 0.000 description 28
- 125000001424 substituent group Chemical group 0.000 description 22
- 125000000217 alkyl group Chemical group 0.000 description 18
- 125000000623 heterocyclic group Chemical group 0.000 description 17
- 125000002837 carbocyclic group Chemical group 0.000 description 15
- 229920006395 saturated elastomer Polymers 0.000 description 13
- 125000005842 heteroatom Chemical group 0.000 description 10
- 125000001183 hydrocarbyl group Chemical group 0.000 description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 7
- -1 2-hydroxyphenyl Chemical group 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 229940034982 antineoplastic agent Drugs 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 125000005336 allyloxy group Chemical group 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- UNDYVEDXFDFDRI-UHFFFAOYSA-N 1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one Chemical compound COC1=CC(C(=O)C=C)=CC(OC)=C1OC UNDYVEDXFDFDRI-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- LAWDSOAXOCOSPV-UHFFFAOYSA-N 3-(3-methylbut-2-enoxy)-4-(3-phenylprop-2-enoyl)xanthen-9-one Chemical compound CC(C)=CCOC1=CC=C(C(C2=CC=CC=C2O2)=O)C2=C1C(=O)C=CC1=CC=CC=C1 LAWDSOAXOCOSPV-UHFFFAOYSA-N 0.000 description 1
- CXKQXJPYPVCTRV-UHFFFAOYSA-N 3-(3-methylbut-2-enoxy)-4-[3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]xanthen-9-one Chemical compound COC1=C(OC)C(OC)=CC(C=CC(=O)C=2C3=C(C(C4=CC=CC=C4O3)=O)C=CC=2OCC=C(C)C)=C1 CXKQXJPYPVCTRV-UHFFFAOYSA-N 0.000 description 1
- AEQVLDDVEGAKDQ-UHFFFAOYSA-N 4-(3-phenylprop-2-enoyl)-3-prop-2-enoxyxanthen-9-one Chemical compound C=CCOC1=CC=C(C(C2=CC=CC=C2O2)=O)C2=C1C(=O)C=CC1=CC=CC=C1 AEQVLDDVEGAKDQ-UHFFFAOYSA-N 0.000 description 1
- NVLXRSGZLQABNZ-UHFFFAOYSA-N 4-[3-(3-methoxyphenyl)prop-2-enoyl]-3-(3-methylbut-2-enoxy)xanthen-9-one Chemical compound COC1=CC=CC(C=CC(=O)C=2C3=C(C(C4=CC=CC=C4O3)=O)C=CC=2OCC=C(C)C)=C1 NVLXRSGZLQABNZ-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001680 trimethoxyphenyl group Chemical group 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9920910.8A GB9920910D0 (en) | 1999-09-03 | 1999-09-03 | Novel chalcones |
| GB9920910.8 | 1999-09-03 | ||
| PCT/EP2000/008366 WO2001017988A1 (en) | 1999-09-03 | 2000-08-28 | Novel chalcones |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003508527A JP2003508527A (ja) | 2003-03-04 |
| JP2003508527A5 true JP2003508527A5 (enExample) | 2007-09-06 |
Family
ID=10860346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001522211A Withdrawn JP2003508527A (ja) | 1999-09-03 | 2000-08-28 | 新規カルコン類 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6620842B2 (enExample) |
| EP (1) | EP1212315B1 (enExample) |
| JP (1) | JP2003508527A (enExample) |
| KR (1) | KR100819576B1 (enExample) |
| CN (1) | CN1177843C (enExample) |
| AT (1) | ATE235483T1 (enExample) |
| AU (1) | AU776226B2 (enExample) |
| CA (1) | CA2382130A1 (enExample) |
| CZ (1) | CZ2002787A3 (enExample) |
| DE (1) | DE60001851T2 (enExample) |
| DK (1) | DK1212315T3 (enExample) |
| ES (1) | ES2193106T3 (enExample) |
| GB (1) | GB9920910D0 (enExample) |
| HK (1) | HK1043999B (enExample) |
| HU (1) | HUP0202579A3 (enExample) |
| NO (1) | NO20021049L (enExample) |
| PL (1) | PL353064A1 (enExample) |
| PT (1) | PT1212315E (enExample) |
| RU (1) | RU2252938C2 (enExample) |
| SK (1) | SK3112002A3 (enExample) |
| WO (1) | WO2001017988A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101052816B1 (ko) | 2002-04-17 | 2011-07-29 | 스미스 클라인 비참 코포레이션 | 화합물, 조성물 및 방법 |
| US7638554B2 (en) * | 2002-04-18 | 2009-12-29 | Sri International | Flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents |
| US20030229136A1 (en) * | 2002-04-18 | 2003-12-11 | Nurulain Zaveri | Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents |
| JP2005533119A (ja) | 2002-07-17 | 2005-11-04 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、及び方法 |
| US6864264B1 (en) | 2002-08-20 | 2005-03-08 | Gloria L. Anderson | 1-adamantyl chalcones for the treatment of proliferative disorders |
| CN100336797C (zh) * | 2005-08-19 | 2007-09-12 | 浙江大学 | 四取代查耳酮衍生物及制备方法和用途 |
| CN104169267B (zh) * | 2012-03-01 | 2017-03-01 | 香港理工大学 | 含炔烃的类黄酮、含叠氮化物的类黄酮和含三唑的类黄酮作为调节剂用于癌症的多药耐药 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI912995A0 (fi) * | 1988-12-21 | 1991-06-19 | Upjohn Co | Atiaterosklerotiska och antirombotiska 1-benzopyran-4-oner och 2-amino-1,3-benzoxazin-4-oner. |
| US5023341A (en) * | 1989-09-19 | 1991-06-11 | Allergan, Inc. | Compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity |
| US4996230A (en) * | 1990-02-16 | 1991-02-26 | Eli Lilly And Company | Leukotriene antagonists |
| JPH05509078A (ja) * | 1990-05-17 | 1993-12-16 | ベイラー カレッジ オブ メディシン | 成長抑制因とガンおよび細胞増殖性疾患措置法 |
| IT1271301B (it) * | 1994-12-20 | 1997-05-27 | Indena Spa | Calconi naturali e sintetici e loro esteri ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno e formulazioni che li contengono |
| US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
-
1999
- 1999-09-03 GB GBGB9920910.8A patent/GB9920910D0/en not_active Ceased
-
2000
- 2000-08-28 ES ES00964042T patent/ES2193106T3/es not_active Expired - Lifetime
- 2000-08-28 PT PT00964042T patent/PT1212315E/pt unknown
- 2000-08-28 EP EP00964042A patent/EP1212315B1/en not_active Expired - Lifetime
- 2000-08-28 HK HK02105661.5A patent/HK1043999B/en unknown
- 2000-08-28 AT AT00964042T patent/ATE235483T1/de not_active IP Right Cessation
- 2000-08-28 SK SK311-2002A patent/SK3112002A3/sk unknown
- 2000-08-28 JP JP2001522211A patent/JP2003508527A/ja not_active Withdrawn
- 2000-08-28 DK DK00964042T patent/DK1212315T3/da active
- 2000-08-28 CA CA002382130A patent/CA2382130A1/en not_active Abandoned
- 2000-08-28 WO PCT/EP2000/008366 patent/WO2001017988A1/en not_active Ceased
- 2000-08-28 PL PL00353064A patent/PL353064A1/xx not_active IP Right Cessation
- 2000-08-28 CN CNB008123039A patent/CN1177843C/zh not_active Expired - Fee Related
- 2000-08-28 DE DE60001851T patent/DE60001851T2/de not_active Expired - Fee Related
- 2000-08-28 KR KR1020027002798A patent/KR100819576B1/ko not_active Expired - Fee Related
- 2000-08-28 AU AU75109/00A patent/AU776226B2/en not_active Ceased
- 2000-08-28 RU RU2002108566/04A patent/RU2252938C2/ru not_active IP Right Cessation
- 2000-08-28 HU HU0202579A patent/HUP0202579A3/hu unknown
- 2000-08-28 CZ CZ2002787A patent/CZ2002787A3/cs unknown
-
2002
- 2002-02-15 US US10/075,626 patent/US6620842B2/en not_active Expired - Fee Related
- 2002-03-01 NO NO20021049A patent/NO20021049L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003508524A5 (enExample) | ||
| JP2008514732A5 (enExample) | ||
| JP2003508523A5 (enExample) | ||
| JP2001526218A5 (enExample) | ||
| JP2003523927A5 (enExample) | ||
| JP2006528685A5 (enExample) | ||
| NO20032510L (no) | Organiske forbindelser | |
| JP2004531544A5 (enExample) | ||
| JP2003521514A5 (enExample) | ||
| JP2002030084A5 (enExample) | ||
| JP2003502367A5 (enExample) | ||
| JP2003508527A5 (enExample) | ||
| RU2002108567A (ru) | Халконовые кумарины | |
| JP2006508965A5 (enExample) | ||
| RU2002130247A (ru) | Производные оксадиазола, обладающие противоопухолевым действием | |
| RU2000101307A (ru) | Халконы, обладающие антипролиферативной активностью | |
| JP2005526773A5 (enExample) | ||
| JP2024112835A5 (enExample) | ||
| JP2002539089A5 (enExample) | ||
| JP2003513075A5 (enExample) | ||
| RU2007125130A (ru) | Применение атазанавира для улучшения фармакокинетики лекарственных средств, метаболизируемых ugt1a1 | |
| JP2008521934A5 (enExample) | ||
| RU2007101238A (ru) | Пептидные агонисты вазопрессинового рецептора | |
| JP2003522171A5 (enExample) | ||
| JPH1036365A5 (enExample) |